NASDAQ:BLUE - bluebird bio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$187.00 -2.40 (-1.27 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$189.40
Today's Range$186.05 - $191.95
52-Week Range$74.45 - $236.17
Volume497,257 shs
Average Volume776,523 shs
Market Capitalization$9.30 billion
P/E Ratio-24.25
Dividend YieldN/A
Beta2.17

About bluebird bio (NASDAQ:BLUE)

bluebird bio logobluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLUE
CUSIPN/A
Phone339-499-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio10.80
Quick Ratio10.80

Price-To-Earnings

Trailing P/E Ratio-24.25
Forward P/E Ratio-20.04
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.43 million
Price / Sales264.53
Cash FlowN/A
Price / CashN/A
Book Value$31.33 per share
Price / Book5.97

Profitability

EPS (Most Recent Fiscal Year)($7.71)
Net Income$-335,640,000.00
Net Margins-857.55%
Return on Equity-27.61%
Return on Assets-23.05%

Miscellaneous

Employees479
Outstanding Shares50,120,000

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio (NASDAQ:BLUE) released its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($2.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by $0.30. The biotechnology company earned $15.96 million during the quarter, compared to the consensus estimate of $5.85 million. bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The business's revenue was up 133.7% compared to the same quarter last year. During the same period last year, the company posted ($1.68) earnings per share. View bluebird bio's Earnings History.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for bluebird bio.

What price target have analysts set for BLUE?

23 brokers have issued 12-month target prices for bluebird bio's stock. Their forecasts range from $102.00 to $250.00. On average, they expect bluebird bio's share price to reach $199.8947 in the next twelve months. View Analyst Ratings for bluebird bio.

What are Wall Street analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:
  • 1. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (3/20/2018)
  • 2. Maxim Group analysts commented, "bluebird reported YE-2017 with $22M in revenue (collaborative/licensing revenue) and a net loss of $336M. Operating expenses have increased as clinical programs advance to later stages of development. The company ended the period with $1.6B in cash, sufficient runway into 2021 at the current burn rate." (2/22/2018)
  • 3. Cantor Fitzgerald analysts commented, "Lining Up for Three Marketing Applications. bluebird plans to file for European approval of LentiGlobin in transfusion-dependent b-thalassemia (non-b0/b0) in 2H18, followed by bb2121 in relapsed/refractory multiple myeloma and Lenti-D in cerebral adrenoleukodystrophy in 2019. As a reminder, bb2121 is being investigated in a Phase 3 study, KarMMa, which is being conducted by bluebird’s bb2121 development partner, Celgene (CELG – Neutral, covered by Mara Goldstein)." (2/21/2018)
  • 4. Morgan Stanley analysts commented, "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded Bluebird's stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to "increase investor confidence" in its sickle cell gene therapy."Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially," the analyst explained. "We do not believe the evidence supports current investor optimism that this can be solved by ASH." (10/2/2017)

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 45)
  • Mr. Jeffrey T. Walsh, Chief Financial & Strategy Officer and Treasurer (Age 52)
  • Ms. Susanna Gatti High, Chief Operating Officer (Age 50)
  • Dr. Philip D. Gregory D. Phil., Chief Scientific Officer (Age 47)
  • Dr. David M. Davidson M.D., Chief Medical Officer (Age 54)

Has bluebird bio been receiving favorable news coverage?

News articles about BLUE stock have trended somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. bluebird bio earned a news sentiment score of 0.06 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.73 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.06%), BlackRock Inc. (7.72%), OppenheimerFunds Inc. (1.54%), Northern Trust Corp (1.18%), Victory Capital Management Inc. (1.11%) and Franklin Resources Inc. (0.76%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

Which institutional investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., OppenheimerFunds Inc., Baillie Gifford & Co., Victory Capital Management Inc., Neuberger Berman Group LLC, Lord Abbett & CO. LLC, Point72 Asset Management L.P. and Artal Group S.A.. Company insiders that have sold bluebird bio company stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Insider Buying and Selling for bluebird bio.

Which institutional investors are buying bluebird bio stock?

BLUE stock was acquired by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Amundi Pioneer Asset Management Inc., BlackRock Inc., Schwab Charles Investment Management Inc., UBS Group AG, GSA Capital Partners LLP, Mackay Shields LLC and Allianz Asset Management GmbH. View Insider Buying and Selling for bluebird bio.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $187.00.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $9.30 billion and generates $35.43 million in revenue each year. The biotechnology company earns $-335,640,000.00 in net income (profit) each year or ($7.71) on an earnings per share basis. bluebird bio employs 479 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]


MarketBeat Community Rating for bluebird bio (BLUE)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  672 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  957
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

bluebird bio (NASDAQ:BLUE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
23 Wall Street analysts have issued ratings and price targets for bluebird bio in the last 12 months. Their average twelve-month price target is $199.8947, suggesting that the stock has a possible upside of 6.90%. The high price target for BLUE is $250.00 and the low price target for BLUE is $102.00. There are currently 3 sell ratings, 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.392.392.452.57
Ratings Breakdown: 3 Sell Rating(s)
8 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
8 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $199.8947$199.7368$175.9474$131.70
Price Target Upside: 6.90% upside14.30% upside15.17% downside19.30% downside

bluebird bio (NASDAQ:BLUE) Consensus Price Target History

Price Target History for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018Cantor FitzgeraldReiterated RatingUnderweightLowView Rating Details
5/7/2018Sanford C. BernsteinReiterated RatingMarket Perform$211.00LowView Rating Details
5/3/2018Maxim GroupSet Price TargetHold$200.00HighView Rating Details
5/3/2018BMO Capital MarketsLower Price TargetOutperform ➝ Buy$222.00 ➝ $216.00HighView Rating Details
5/3/2018BTIG ResearchReiterated RatingBuyHighView Rating Details
4/19/2018SunTrust BanksBoost Price TargetBuy$232.00HighView Rating Details
3/28/2018Canaccord GenuityReiterated RatingBuyLowView Rating Details
3/21/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$152.00 ➝ $209.00HighView Rating Details
3/16/2018William BlairReiterated RatingBuyMediumView Rating Details
3/16/2018UBSInitiated CoverageSellHighView Rating Details
3/14/2018Janney Montgomery ScottInitiated CoverageNeutral ➝ Neutral$220.00MediumView Rating Details
2/22/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$185.00 ➝ $218.00MediumView Rating Details
1/25/2018Leerink SwannDowngradeOutperform ➝ Market Perform$162.00 ➝ $194.00LowView Rating Details
1/9/2018OppenheimerReiterated RatingHoldLowView Rating Details
12/21/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformHighView Rating Details
12/13/2017BarclaysReiterated RatingOverweight ➝ Overweight$162.00 ➝ $209.00HighView Rating Details
12/12/2017Wells Fargo & CoReiterated RatingOutperform$190.00 ➝ $242.00HighView Rating Details
12/11/2017Jefferies GroupUpgradeHold ➝ Buy$130.00 ➝ $211.00HighView Rating Details
11/2/2017WedbushReiterated RatingOutperform$135.00 ➝ $174.00N/AView Rating Details
10/16/2017Evercore ISIUpgradeIn-Line ➝ Outperform$102.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingBuy ➝ Buy$186.00N/AView Rating Details
8/31/2017CowenReiterated RatingOutperformHighView Rating Details
6/16/2017Standpoint ResearchReiterated RatingBuy ➝ Reduce$110.00LowView Rating Details
2/23/2017Roth CapitalSet Price TargetHold$71.00N/AView Rating Details
12/7/2016JPMorgan Chase & Co.Reiterated RatingBuy$120.00N/AView Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

bluebird bio (NASDAQ:BLUE) Earnings History and Estimates Chart

Earnings by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE) Earnings Estimates

2018 EPS Consensus Estimate: ($9.15)
2019 EPS Consensus Estimate: ($11.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($2.26)($1.77)($2.01)
Q2 20185($2.55)($2.05)($2.31)
Q3 20185($2.67)($2.13)($2.38)
Q4 20185($2.81)($2.17)($2.45)
Q1 20192($3.02)($2.81)($2.92)
Q2 20192($3.13)($2.95)($3.04)
Q3 20192($3.17)($2.58)($2.88)
Q4 20192($2.87)($2.51)($2.69)

bluebird bio (NASDAQ BLUE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($2.32)N/AView Earnings Details
5/7/2018Q1 2018($2.01)($2.31)$5.85 million$15.96 millionViewN/AView Earnings Details
2/21/2018Q4 2017($1.68)($2.52)$7.11 million$4.17 millionViewN/AView Earnings Details
11/1/2017Q3 2017($1.68)($1.7260)$8.47 million$7.71 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.66)($1.73)$6.29 million$16.70 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.7610)($1.68)$1.51 million$6.83 millionViewN/AView Earnings Details
2/22/2017Q4 2016($1.86)($1.88)$1.76 million$1.55 millionViewN/AView Earnings Details
11/2/2016Q3 2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
11/4/2015Q3($0.96)($1.18)$5.63 million$1.30 millionViewListenView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.68)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.62)($0.66)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.52)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)$6.20 million$6.34 millionViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

bluebird bio (NASDAQ:BLUE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

bluebird bio (NASDAQ BLUE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.00%
Insider Trading History for bluebird bio (NASDAQ:BLUE)
Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ BLUE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/2/2018David DavidsonInsiderSell13,000$177.52$2,307,760.0037,905View SEC Filing  
4/12/2018David DavidsonInsiderSell3,000$180.17$540,510.0027,905View SEC Filing  
4/2/2018David DavidsonInsiderSell22,000$167.52$3,685,440.00View SEC Filing  
3/15/2018Mark VachonDirectorSell6,000$214.38$1,286,280.007,000View SEC Filing  
3/1/2018Philip D GregoryInsiderSell2,250$200.00$450,000.0032,522View SEC Filing  
2/2/2018David DavidsonInsiderSell4,000$202.36$809,440.00View SEC Filing  
1/30/2018Jason ColeInsiderSell25,000$195.91$4,897,750.0044,798View SEC Filing  
1/30/2018Susanna Gatti HighCOOSell17,262$195.91$3,381,798.4228,512View SEC Filing  
1/8/2018David DavidsonInsiderSell3,522$173.61$611,454.4213,959View SEC Filing  
1/5/2018Jason ColeInsiderSell1,129$173.38$195,746.0219,945View SEC Filing  
1/5/2018Nick LeschlyCEOSell5,435$173.38$942,320.30171,009View SEC Filing  
1/3/2018David DavidsonInsiderSell6,000$180.30$1,081,800.0021,977View SEC Filing  
12/13/2017Nick LeschlyInsiderSell117,500$184.08$21,629,400.00293,232View SEC Filing  
12/11/2017Jeffrey T WalshInsiderSell9,900$216.54$2,143,746.0037,205View SEC Filing  
12/11/2017Mark VachonDirectorSell7,000$216.64$1,516,480.008,000View SEC Filing  
12/1/2017Philip D GregoryInsiderSell2,250$172.54$388,215.0028,734View SEC Filing  
12/1/2017Susanna Gatti HighCOOSell1,282$172.15$220,696.3013,718View SEC Filing  
11/10/2017Jeffrey T WalshInsiderSell9,900$149.58$1,480,842.0028,798View SEC Filing  
11/1/2017Jeffrey T WalshInsiderSell35,000$151.38$5,298,300.0062,305View SEC Filing  
11/1/2017Nick LeschlyCEOSell2,127$145.17$308,776.59257,486View SEC Filing  
10/23/2017Nick LeschlyInsiderSell7,050$145.14$1,023,237.00259,059View SEC Filing  
10/20/2017Nick LeschlyCEOSell3,350$145.02$485,817.00259,059View SEC Filing  
10/17/2017Nick LeschlyCEOSell10,823$145.05$1,569,876.15262,409View SEC Filing  
10/10/2017Jeffrey T WalshInsiderSell4,900$129.94$636,706.00View SEC Filing  
10/2/2017David DavidsonInsiderSell4,000$131.31$525,240.00View SEC Filing  
9/14/2017John MaraganoreDirectorSell18,868$131.21$2,475,670.2824,711View SEC Filing  
9/12/2017Mark VachonDirectorSell6,000$126.82$760,920.008,000View SEC Filing  
9/11/2017Jeffrey T WalshInsiderSell4,900$125.73$616,077.0032,205View SEC Filing  
9/1/2017Nick LeschlyInsiderSell46,833$122.27$5,726,270.91289,368View SEC Filing  
8/31/2017Daniel LynchDirectorSell500$120.00$60,000.003,300View SEC Filing  
8/31/2017Jeffrey T WalshInsiderSell12,000$125.01$1,500,120.0039,305View SEC Filing  
8/30/2017Nick LeschlyInsiderSell25,667$115.18$2,956,325.06339,368View SEC Filing  
8/28/2017Jeffrey T WalshInsiderSell1,250$107.06$133,825.0028,555View SEC Filing  
8/14/2017James MandellDirectorSell1,000$95.95$95,950.001,000View SEC Filing  
8/10/2017Jeffrey T WalshInsiderSell1,250$95.41$119,262.5028,555View SEC Filing  
8/7/2017Philip D GregoryInsiderSell750$99.00$74,250.0031,234View SEC Filing  
8/4/2017Eric SullivanInsiderSell861$93.83$80,787.635,924View SEC Filing  
8/1/2017David DavidsonInsiderSell3,000$92.37$277,110.0018,977View SEC Filing  
7/10/2017Jeffrey T WalshInsiderSell2,500$99.89$249,725.0029,805View SEC Filing  
7/7/2017David DavidsonInsiderSell1,200$100.49$120,588.0016,077View SEC Filing  
7/6/2017Philip D GregoryInsiderSell2,250$103.83$233,617.5033,734View SEC Filing  
7/5/2017David DavidsonInsiderSell5,000$105.28$526,400.0022,177View SEC Filing  
6/29/2017Eric SullivanInsiderSell6,787$108.96$739,511.528,466View SEC Filing  
6/27/2017Nick LeschlyInsiderSell25,000$108.05$2,701,250.00360,656View SEC Filing  
6/23/2017Daniel LynchDirectorSell4,000$109.09$436,360.004,808View SEC Filing  
6/20/2017Daniel LynchDirectorSell2,500$120.03$300,075.005,300View SEC Filing  
6/7/2017Jason ColeInsiderSell17,245$100.22$1,728,293.9030,871View SEC Filing  
6/6/2017Daniel LynchDirectorSell2,263$100.14$226,616.823,663View SEC Filing  
6/6/2017Philip D GregoryInsiderSell1,500$99.04$148,560.0037,279View SEC Filing  
6/5/2017David DavidsonInsiderSell1,000$90.00$90,000.0018,177View SEC Filing  
5/25/2017Daniel LynchDirectorSell2,000$80.00$160,000.003,400View SEC Filing  
4/27/2017Daniel LynchDirectorSell1,000$90.01$90,010.002,400View SEC Filing  
4/25/2017Daniel LynchDirectorSell2,000$86.75$173,500.003,400View SEC Filing  
4/10/2017Jeffrey T WalshInsiderSell1,250$87.38$109,225.0028,555View SEC Filing  
4/3/2017David DavidsonInsiderSell3,000$90.89$272,670.0020,177View SEC Filing  
3/27/2017Daniel LynchDirectorSell3,000$88.12$264,360.003,400View SEC Filing  
3/16/2017Daniel LynchDirectorSell237$100.07$23,716.591,637View SEC Filing  
3/16/2017Jason ColeInsiderSell4,930$100.07$493,345.1016,981View SEC Filing  
3/3/2017John MaraganoreDirectorSell13,839$85.02$1,176,591.785,765View SEC Filing  
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.001,550View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.5212,051View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.502,250View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.7212,717View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.009,000View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.002,400View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.0014,677View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.909,389View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.005,891View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.005,891View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.005,891View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.124,456View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.284,656View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.0010,600View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.1230,069View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.0010,600View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.0010,600View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.0010,600View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.0010,600View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.001,000View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50313,241View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00246,521View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00304,318View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

bluebird bio (NASDAQ BLUE) News Headlines

Source:
DateHeadline
bluebird bio, Inc.bluebird bio, Inc.
www.streetinsider.com - May 24 at 10:33 AM
bluebirds Lenti-D Gets Breakthrough Therapy Status From FDAbluebird's Lenti-D Gets Breakthrough Therapy Status From FDA
www.zacks.com - May 24 at 10:33 AM
bluebird bio (BLUE) Granted FDA Breakthrough Therapy for Lenti-D to Treat Cerebral Adrenoleukodystrophybluebird bio (BLUE) Granted FDA Breakthrough Therapy for Lenti-D to Treat Cerebral Adrenoleukodystrophy
www.streetinsider.com - May 24 at 10:33 AM
bluebird bio (BLUE) Expected to Post FY2018 Earnings of ($10.22) Per Sharebluebird bio (BLUE) Expected to Post FY2018 Earnings of ($10.22) Per Share
www.americanbankingnews.com - May 24 at 8:36 AM
Interesting BLUE Put And Call Options For July 20thInteresting BLUE Put And Call Options For July 20th
www.nasdaq.com - May 23 at 3:46 PM
Bluebird bios Lenti-D a Breakthrough Therapy for rare neurological disorder; shares up 2%Bluebird bio's Lenti-D a Breakthrough Therapy for rare neurological disorder; shares up 2%
seekingalpha.com - May 23 at 9:55 AM
FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral AdrenoleukodystrophyFDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy
finance.yahoo.com - May 23 at 9:55 AM
bluebird bio (BLUE) Given Average Recommendation of "Hold" by Brokeragesbluebird bio (BLUE) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 21 at 11:35 AM
bluebird bio (BLUE) Stock Rating Reaffirmed by Cantor Fitzgeraldbluebird bio (BLUE) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - May 19 at 10:56 AM
Is bluebird bio Inc’s (NASDAQ:BLUE) Liquidity Good Enough?Is bluebird bio Inc’s (NASDAQ:BLUE) Liquidity Good Enough?
finance.yahoo.com - May 17 at 3:43 PM
bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory ...bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory ...
www.businesswire.com - May 17 at 10:37 AM
bluebird bio (BLUE) to Present New Data from LentiGlobin Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at EHAbluebird bio (BLUE) to Present New Data from LentiGlobin Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at EHA
www.streetinsider.com - May 17 at 10:37 AM
bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meetingbluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
finance.yahoo.com - May 17 at 10:37 AM
bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Associationbluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association
finance.yahoo.com - May 17 at 10:37 AM
bluebird bio: Gene Therapy Best In Classbluebird bio: Gene Therapy Best In Class
seekingalpha.com - May 16 at 3:48 PM
Bluebird Bio Expands On Partnership To Take A Lead In Immuno-OncologyBluebird Bio Expands On Partnership To Take A Lead In Immuno-Oncology
seekingalpha.com - May 15 at 11:05 AM
bluebird bio (BLUE) Expected to Announce Quarterly Sales of $11.09 Millionbluebird bio (BLUE) Expected to Announce Quarterly Sales of $11.09 Million
www.americanbankingnews.com - May 15 at 4:40 AM
Medigene in for up to $1.5 bln under broader pact with Bluebird BioMedigene in for up to $1.5 bln under broader pact with Bluebird Bio
finance.yahoo.com - May 14 at 11:37 AM
Medigene expands partnership with bluebird bioMedigene expands partnership with bluebird bio
seekingalpha.com - May 14 at 11:37 AM
Medigene in for up to $1.5 billion under broader pact with Bluebird BioMedigene in for up to $1.5 billion under broader pact with Bluebird Bio
www.reuters.com - May 14 at 11:37 AM
bluebird bio (BLUE) Expected to Announce Earnings of -$2.27 Per Sharebluebird bio (BLUE) Expected to Announce Earnings of -$2.27 Per Share
www.americanbankingnews.com - May 13 at 3:19 AM
bluebird bio Looks for Data Aheadbluebird bio Looks for Data Ahead
finance.yahoo.com - May 10 at 10:41 AM
bluebird bio Inc (NASDAQ:BLUE) Is Expected To Breakevenbluebird bio Inc (NASDAQ:BLUE) Is Expected To Breakeven
finance.yahoo.com - May 7 at 3:48 PM
bluebird bio (BLUE) Given Market Perform Rating at Sanford C. Bernsteinbluebird bio (BLUE) Given Market Perform Rating at Sanford C. Bernstein
www.americanbankingnews.com - May 7 at 2:57 PM
bluebird bio (BLUE) PT Lowered to $175 at Evercore ISIbluebird bio (BLUE) PT Lowered to $175 at Evercore ISI
www.streetinsider.com - May 7 at 10:34 AM
bluebird bio (BLUE) Expected to Post FY2022 Earnings of $14.11 Per Sharebluebird bio (BLUE) Expected to Post FY2022 Earnings of $14.11 Per Share
www.americanbankingnews.com - May 7 at 5:20 AM
Q2 2018 Earnings Estimate for bluebird bio (BLUE) Issued By OppenheimerQ2 2018 Earnings Estimate for bluebird bio (BLUE) Issued By Oppenheimer
www.americanbankingnews.com - May 7 at 2:44 AM
Q2 2018 Earnings Forecast for bluebird bio (BLUE) Issued By William BlairQ2 2018 Earnings Forecast for bluebird bio (BLUE) Issued By William Blair
www.americanbankingnews.com - May 7 at 2:44 AM
SunTrust Banks Research Analysts Lower Earnings Estimates for bluebird bio (BLUE)SunTrust Banks Research Analysts Lower Earnings Estimates for bluebird bio (BLUE)
www.americanbankingnews.com - May 7 at 2:44 AM
bluebird bio (BLUE) Insider David Davidson Sells 13,000 Sharesbluebird bio (BLUE) Insider David Davidson Sells 13,000 Shares
www.americanbankingnews.com - May 4 at 7:34 PM
bluebird bio (BLUE) Stock Rating Upgraded by ValuEnginebluebird bio (BLUE) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 3 at 10:32 PM
bluebird bio (BLUE) Price Target Cut to $216.00bluebird bio (BLUE) Price Target Cut to $216.00
www.americanbankingnews.com - May 3 at 8:35 PM
bluebird bio (BLUE) Receives "Buy" Rating from BTIG Researchbluebird bio (BLUE) Receives "Buy" Rating from BTIG Research
www.americanbankingnews.com - May 3 at 4:31 PM
bluebird bio (BLUE) PT Set at $200.00 by Maxim Groupbluebird bio (BLUE) PT Set at $200.00 by Maxim Group
www.americanbankingnews.com - May 3 at 12:52 PM
BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $2.31BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $2.31
www.reuters.com - May 3 at 10:12 AM
Bluebird: 1Q Earnings SnapshotBluebird: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 10:12 AM
bluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progressbluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress
finance.yahoo.com - May 3 at 10:12 AM
bluebird bio (BLUE) Announces Quarterly  Earnings Results, Misses Estimates By $0.30 EPSbluebird bio (BLUE) Announces Quarterly Earnings Results, Misses Estimates By $0.30 EPS
www.americanbankingnews.com - May 2 at 10:46 PM
bluebird bio Inc (NASDAQ:BLUE): Does The Earnings Decline Make It An Underperformer?bluebird bio Inc (NASDAQ:BLUE): Does The Earnings Decline Make It An Underperformer?
finance.yahoo.com - May 1 at 3:42 PM
bluebird bio (BLUE) Expected to Announce Quarterly Sales of $5.77 Millionbluebird bio (BLUE) Expected to Announce Quarterly Sales of $5.77 Million
www.americanbankingnews.com - April 27 at 2:40 AM
bluebird bio (BLUE) Receives Consensus Rating of "Hold" from Analystsbluebird bio (BLUE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 26 at 12:08 PM
Zacks: Brokerages Anticipate bluebird bio (BLUE) Will Post Earnings of -$1.99 Per ShareZacks: Brokerages Anticipate bluebird bio (BLUE) Will Post Earnings of -$1.99 Per Share
www.americanbankingnews.com - April 25 at 3:14 PM
bluebird bio (BLUE) Scheduled to Post Quarterly Earnings on Tuesdaybluebird bio (BLUE) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 6:52 AM
Bluebird Bio Impresses Yet Again With Gene Therapy PlatformBluebird Bio Impresses Yet Again With Gene Therapy Platform
seekingalpha.com - April 23 at 10:16 AM
bluebird bio (BLUE) to Post FY2019 Earnings of ($6.89) Per Share, SunTrust Banks Forecastsbluebird bio (BLUE) to Post FY2019 Earnings of ($6.89) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - April 23 at 2:48 AM
Janney Montgomery Scott Analysts Give bluebird bio (BLUE) a $125.00 Price TargetJanney Montgomery Scott Analysts Give bluebird bio (BLUE) a $125.00 Price Target
www.americanbankingnews.com - April 20 at 1:55 PM
Why Investment Wealth-Builders Disdain Big Pharma Stocks NowWhy Investment Wealth-Builders Disdain Big Pharma Stocks Now
seekingalpha.com - April 20 at 10:45 AM
Is bluebird bio One Step Closer to Its First Commercial Drug?Is bluebird bio One Step Closer to Its First Commercial Drug?
www.msn.com - April 20 at 10:45 AM
Gene therapy helps patients avoid blood transfusion, study saysGene therapy helps patients avoid blood transfusion, study says
www.cnn.com - April 19 at 10:30 AM
bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemiabluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
finance.yahoo.com - April 19 at 10:30 AM

SEC Filings

bluebird bio (NASDAQ:BLUE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

bluebird bio (NASDAQ:BLUE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

bluebird bio (NASDAQ BLUE) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.